Syngene International's Q2 FY 2025-26 Quarterly Results

Result Summary

• Syngene International Ltd reported a 3.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 2.0%.
• Its expenses for the quarter were up by 6.3% QoQ and 9.2% YoY.
• The net profit decreased 22.6% QoQ and decreased 36.8% YoY.
• The earnings per share (EPS) of Syngene International Ltd stood at 1.67 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Syngene International Ltd is a leading contract research and manufacturing organization (CRMO) offering integrated scientific solutions from early discovery to commercial supply. The company primarily operates within the pharmaceutical and biotechnology industries, providing services such as drug discovery, development, and manufacturing. Syngene partners with global pharmaceutical, biotechnology, and chemical companies to deliver end-to-end solutions. The company is recognized for its scientific expertise, state-of-the-art infrastructure, and robust quality systems. Recent developments in the industry and company are not available in the provided data, hence any updates post-October 2023 are not included in this report.

Revenue

In the second quarter of fiscal year 2026 (Q2FY26), Syngene International Ltd reported a total income of ₹926.00 crores. This represents a sequential increase of 3.8% from the first quarter of fiscal year 2026 (Q1FY26), where the total income was ₹892.20 crores. Compared to the second quarter of fiscal year 2025 (Q2FY25), where the total income was ₹907.50 crores, there is a year-over-year increase of 2.0%. The increase in revenue both on a quarterly and yearly basis indicates steady growth in the company's income streams over the analyzed periods.

Profitability

For Q2FY26, Syngene International Ltd reported a Profit Before Tax (PBT) of ₹85.20 crores, down 15.9% from ₹101.30 crores in Q1FY26 and down 37.9% from ₹137.30 crores in Q2FY25. The company's Profit After Tax (PAT) for Q2FY26 was ₹67.10 crores, which marks a decline of 22.6% compared to Q1FY26 where the PAT was ₹86.70 crores. On a year-over-year basis, the PAT decreased by 36.8% from ₹106.10 crores in Q2FY25. The earnings per share (EPS) for Q2FY26 stood at ₹1.67, reflecting a decrease of 22.3% from Q1FY26 and 36.7% from Q2FY25. These figures highlight a reduction in profitability compared to both the previous quarter and the same quarter last year.

Operating Metrics

The total expenses for Q2FY26 were ₹840.80 crores, which shows an increase of 6.3% from ₹790.90 crores in Q1FY26 and 9.2% from ₹770.20 crores in Q2FY25. The tax expense for Q2FY26 was ₹18.10 crores, up 24.0% from Q1FY26, yet down 42.0% from Q2FY25. The increase in total expenses on both a quarterly and yearly basis contrasts with the trends in profitability metrics. The data indicates a scenario where expenses have risen more significantly than income, affecting the overall profitability of Syngene International Ltd during the analyzed periods.